40.6

Million Dollars

in 2020 revenue from FC2

17.66

Million Dollars

worth of FC2 prescription in US and globally

150

Countries

The number of countries in which FC2 is sold


The Path to Drawdown: Contraceptives

About

Veru, Inc. (stock ticker: VERU) is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. They also offer FC2 female condoms that are FDA-approved and cleared by the World Health Organization for purchase by the United Nations. Veru is headquartered in Miami, Florida.

VERU's Role in Drawdown

Veru's Sexual Health Division makes FC2, a female condom for the dual protection against unintended pregnancy and sexually transmitted infections. FC2 is sold commercially in the US and in the public health sector in the US and internationally.  

VERU: What We Like

We'll update this section once Veru makes sustainability information available.

VERU: What We Want to See Improve

Coming soon!


Other Contraceptives Stocks in the Climate Index

Attend Our Next Webinar

Attend Our Next Webinar

Join our next Sustainable Investing 101 webinar, get our favorite DIY options, and walk through how we build our portfolios.

Register
Get Our Newsletter

Get Our Newsletter

Go a level deeper with us and investigate the potential impacts of climate change on investments like your retirement account.

Join Newsletter
Talk To A Human

Talk To A Human

Joining a new investment service can be intimidating. We’re here for you. Click below to email us a question or book a quick call.

Ask a Question